Michael Kauffman
Chairman bei BIVICTRIX THERAPEUTICS PLC
Vermögen: 85 902 $ am 31.03.2024
Profil
Michael G.
Kauffman was the founder of Karyopharm Therapeutics, Inc. (founded in 2008) and held the title of Director.
He is also the founder of Millennium Predictive Medicine, Inc. Dr. Kauffman's current job positions include President, Chief Executive Officer & Director at Nereid Therapeutics, Inc. (since 2023), Chairman at Verastem, Inc. (since 2012), Non-Executive Chairman at BiVictriX Therapeutics Plc (since 2022), Independent Director at Kezar Life Sciences, Inc. (since 2016), Independent Director at Adicet Bio, Inc. (since 2021), Director at Mirror Biologics Inc, and Advisor at Prime Movers Lab LLC.
His former job positions include Chief Executive Officer at EPIX Pharmaceuticals, Inc. (2006-2008), Chief Executive Officer at Predix Pharmaceuticals, Inc. (2002-2006), Medical Director at Biogen, Inc. (1995-1997), Director at CombinatoRx, Inc. (2006-2009), Director at Metamark Genetics, Inc. (2012), Independent Director at Infinity Pharmaceuticals, Inc. (2017-2020), Director at Zalicus, Inc. (2006-2014), Director at Excision BioTherapeutics, Inc., Advisor at Bessemer Venture Partners LP (2009-2010), and Executive Vice President-Distribution Operations at The Jones Group, Inc. He also held the position of Vice President-Clinical at Millennium Pharmaceuticals, Inc. (2000-2002), Chief Medical Officer at Onyx Pharmaceuticals, Inc. (2009-2010), and Chief Medical Officer at Proteolix, Inc. (2008-2009).
Dr. Kauffman's education includes an undergraduate degree from Amherst College and a doctorate degree from The Johns Hopkins University School of Medicine (conferred in 1992).
Dr. Kauffman is also the founder of Millennium Predictive Medicine, Inc...
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
KEZAR LIFE SCIENCES INC
0,09% | 24.07.2023 | 63 690 ( 0,09% ) | 57 448 $ | 31.03.2024 |
ADICET BIO INC
0,01% | 14.08.2023 | 5 900 ( 0,01% ) | 13 865 $ | 31.03.2024 |
| 31.12.2022 | 75 000 ( 0,09% ) | 10 659 $ | 31.03.2024 | |
VERASTEM, INC.
0,00% | 11.03.2024 | 333 ( 0,00% ) | 3 929 $ | 31.03.2024 |
Aktive Positionen von Michael Kauffman
| Unternehmen | Position | Beginn |
|---|---|---|
| VERASTEM, INC. | Chairman | - |
| KEZAR LIFE SCIENCES, INC. | Director/Board Member | 01.12.2016 |
| ADICET BIO, INC. | Director/Board Member | 17.11.2021 |
| BIVICTRIX THERAPEUTICS PLC | Chairman | 06.01.2023 |
Mirror Biologics Inc
 Mirror Biologics Inc BiotechnologyHealth Technology Mirror Biologics Inc manufactures immune modulatory vaccines and therapeutics. The company is based in Tampa, FL. The company was founded in 2019 by Michael Har-Noy. Michael Har-Noy has been the CEO since 2019. | Director/Board Member | - |
Prime Movers Lab LLC
 Prime Movers Lab LLC Investment ManagersFinance Prime Movers Lab LLC (Prime Movers Lab) is a venture capital firm founded in 2018 by Dakin Sloss. The firm is headquartered in Jackson, Wyoming. | Consultant / Advisor | - |
Nereid Therapeutics, Inc.
 Nereid Therapeutics, Inc. BiotechnologyHealth Technology Nereid Therapeutics, Inc. operates as a life sciences venture firm. It translates the potential of biomolecular condensates into life-changing therapeutics. The company was founded by Clifford Brangwynne and Spiros Liras and is headquartered in Cambridge, MA. | Chief Executive Officer | 13.11.2023 |
Ehemalige bekannte Positionen von Michael Kauffman
| Unternehmen | Position | Ende |
|---|---|---|
| KARYOPHARM THERAPEUTICS INC. | Founder | 31.05.2022 |
| INFINITY PHARMACEUTICALS, INC. | Director/Board Member | 16.06.2020 |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Michael Kauffman
| Amherst College | Undergraduate Degree |
| The Johns Hopkins University School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 7 |
|---|---|
| BIOGEN INC. | Health Technology |
| INFINITY PHARMACEUTICALS, INC. | Health Technology |
| KARYOPHARM THERAPEUTICS INC. | Health Technology |
| VERASTEM, INC. | Health Technology |
| KEZAR LIFE SCIENCES, INC. | Health Technology |
| BIVICTRIX THERAPEUTICS PLC | Health Technology |
| ADICET BIO, INC. | Health Technology |
| Private Unternehmen | 15 |
|---|---|
Bessemer Venture Partners LP
 Bessemer Venture Partners LP Investment ManagersFinance Bessemer Venture Partners LP seeks investment opportunities in companies primarily located in the US. The fund focuses on companies with a strong business model, experienced management teams and growth potential. It targets companies operating across a broad range of sectors such as healthcare, information systems, telecommunications, and retailing. It provides financing for seed, early and later stage capital requirements. | Finance |
The Jones Group, Inc.
 The Jones Group, Inc. Apparel/FootwearConsumer Non-Durables The Jones Group, Inc. designs, markets and wholesales brands with product expertise in apparel, footwear, jeanswear, jewelry and handbags. The company markets directly to consumers through its branded specialty retail and outlet stores and through its ecommerce sites. It operates through six segments: Domestic Wholesale Sportswear, Domestic Wholesale Jeanswear, Domestic Wholesale Footwear & Accessories, Domestic Retail, International Wholesale and International Retail. The Domestic Wholesale Sportswear segment's brands cover a broad array of categories for the women's markets which includes career and casual sportswear, jeanswear, dresses, suits, and a combination of all components termed lifestyle collection. The Domestic Wholesale Jeanswear segment's brands cover a broad array of categories for the women's, juniors and girls markets which includes jeanswear, casual sportswear and dresses, with a focus on fit, fabric and finish. The Domestic Wholesale Footwear & Accessories segment operations include the sale of both branded and private label footwear, handbags, small leather goods and costume, semi-precious, sterling silver, and marcasite jewelry. The Domestic Retail segment markets apparel, footwear and accessories directly to consumers through its specialty retail stores operating in malls and urban retail centers, its various value-based stores located in major retail locations, and on several e-commerce web sites that it operates. The International Wholesale segment's operations include the sale of brand-name footwear, handbags, small leather goods, jewelry and apparel to distributors and retailers outside the United States. The International Retail segment markets apparel, footwear and accessories directly to consumers through its specialty retail stores operating in malls and urban retail centers, through its various value-based stores located in major retail locations, through concessions located in department stores and a number of airports and through e-commerce websites accessible to international consumers. The company was founded by Sidney Kimmel in 1970 and is headquartered in New York, NY. | Consumer Non-Durables |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
EPIX Pharmaceuticals, Inc.
 EPIX Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology EPIX Pharmaceuticals, Inc. used to develop targeted contrast agents both to improve the capability and expand the use of magnetic resonance imaging (MRI) as a tool for diagnosing human disease. The company was founded in 1988 and was headquartered in Lexington, MA. | Health Technology |
Predix Pharmaceuticals, Inc.
 Predix Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals, Inc. develops novel drugs and other related products. It is a clinical stage drug development company that uses proprietary discovery and lead optimization engine to develop novel drugs for G-protein coupled receptor (GPCR) and ion channel targets. The company was founded by Silvia Noiman, Haim Aviv, Oren M. Becker and Oren M. Ramot in September, 2002 and is headquartered in Woburn, MA. | Health Technology |
CombinatoRx, Inc.
 CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | Health Technology |
Metamark Genetics, Inc.
 Metamark Genetics, Inc. Medical/Nursing ServicesHealth Services Metamark Genetics, Inc. provides molecular diagnostics services. It develops prognostic and predictive diagnostic tests that will enable personalized treatment planning for cancer patients. It transforms cancer diagnosis and treatment by developing pioneering diagnostic products based on its prognosis determinants platform. The company was founded by Kenneth E. Weg, Raju S. Kucherlapati, David Rimm, Lynda Chin and Ronald A. DePinho in November 2007 and is headquartered in Waltham, MA. | Health Services |
Proteolix, Inc.
 Proteolix, Inc. Pharmaceuticals: MajorHealth Technology Proteolix, Inc. manufactures bio-pharmaceutical related products. It engages in the discovery, development, and marketing of pharmaceutical products to treat cancer and immunological conditions. The company was founded by Susan M. Molineauxf in December 2003 and is headquartered in South San Francisco, CA | Health Technology |
| Millennium Predictive Medicine, Inc. | |
Excision BioTherapeutics, Inc.
 Excision BioTherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Excision BioTherapeutics, Inc. develops gene editing therapeutics for the treatment of life-threatening disease caused by viral infections. The firm focuses on Human Immunodeficiency Virus -1 therapeutics, JC Virus and Progressive Multifocal Leukoencephalopathy, Hepatitis B virus therapeutics, and CRISPR vaccinations?. The company was founded by David Rowe, Kamel Khalili, Thomas Malcolm, and Rob Simmons in 2015 and is headquartered in San Francisco, CA. | Commercial Services |
Prime Movers Lab LLC
Prime Movers Lab LLC Investment ManagersFinance Prime Movers Lab LLC (Prime Movers Lab) is a venture capital firm founded in 2018 by Dakin Sloss. The firm is headquartered in Jackson, Wyoming. | Finance |
Nereid Therapeutics, Inc.
Nereid Therapeutics, Inc. BiotechnologyHealth Technology Nereid Therapeutics, Inc. operates as a life sciences venture firm. It translates the potential of biomolecular condensates into life-changing therapeutics. The company was founded by Clifford Brangwynne and Spiros Liras and is headquartered in Cambridge, MA. | Health Technology |
Mirror Biologics Inc
Mirror Biologics Inc BiotechnologyHealth Technology Mirror Biologics Inc manufactures immune modulatory vaccines and therapeutics. The company is based in Tampa, FL. The company was founded in 2019 by Michael Har-Noy. Michael Har-Noy has been the CEO since 2019. | Health Technology |
Zalicus, Inc.
 Zalicus, Inc. Pharmaceuticals: MajorHealth Technology Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA. | Health Technology |
